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Pancreatic adenocarcinoma is among the most aggressively invasive malignancies. The immunoglobulin superfamily member
carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) is emerging as an important determinant of the malignant
phenotype in a range of cancers. We sought to define the role of CEACAM6 in pancreatic adenocarcinoma cellular invasiveness.
CEACAM6 was stably overexpressed in Capan2 cells, which inherently express low levels of CEACAM6. Retrovirally mediated RNA
interference was used to silence CEACAM6 expression in BxPC3 cells, which inherently overexpress CEACAM6. Cellular
invasiveness was quantified using a modified Boyden chamber assay. Overexpression of CEACAM6 increased Capan2 cellular
invasiveness, whereas CEACAM6 knockdown attenuated BxPC3 invasiveness. A role for the c-Src tyrosine kinase in mediating
CEACAM6-dependent invasiveness was defined using constitutively active and dominant-negative c-Src expression constructs. c-Src-
dependent modulation of matrix metalloproteinase-9 activity contributes significantly to the increased cellular invasiveness induced by
CEACAM6 overexpression. Levels of CEACAM6 expression can modulate pancreatic adenocarcinoma cellular invasiveness in a c-
Src-dependent manner. This pathway warrants further investigation as a target for therapy.
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The outlook for those with pancreatic adenocarcinoma has
improved little over the past decade, despite significant advances
in the perioperative management of patients with this disease
(Postier, 2003). Among the most significant determinants of the
dismal prognosis associated with this malignancy are the highly
aggressive loco-regional invasion and early metastasis that
characterise this malignancy, such that the majority of patients
present with advanced, surgically unresectable disease (Brand,
2001; Tamm and Charnsangavej, 2001). Novel therapeutic
approaches to this malignancy are urgently needed.
Carcinoembryonic antigen-related cell adhesion molecule
6 (CEACAM6) is a glycosylphosphatidylinositol (GPI)-linked
immunoglobulin superfamily member that is overexpressed in
a variety of gastrointestinal malignancies (Kodera et al, 1993;
Jantscheff et al, 2003). Despite lacking a transmembrane or
intracellular domain, CEACAM6 is able to influence intracellular
signalling events and plays an important role in gastrointestinal
cancer progression (Hasegawa et al, 1993; Kodera et al, 1993;
Scholzel et al, 2000; Ilantzis et al, 2002). Pancreatic adenocarci-
noma cells differentially express CEACAM6 and overexpression
of CEACAM6 is associated with greater resistance to anoikis, a
subset of apoptosis induced by inadequate or inappropriate cell
substrate adhesion (Gardner-Thorpe et al, 2002; Duxbury et al,
2004b). Resistance to anoikis is a property of transformed cells that
is associated with greater cellular invasive ability and in vivo
metastatic potential (Yawata et al, 1998; Streuli and Gilmore,
1999; Shanmugathasan and Jothy, 2000; Zhu et al, 2001).
CEACAM6 overexpression is associated with greater resistance
to anoikis and increased metastatic potential, whereas post-
transcriptional inhibition of CEACAM6 expression impairs
the ability of pancreatic adenocarcinoma cells to resist anoikis
and to form experimental liver metastases in vivo (Duxbury et al,
2004b). These features of CEACAM6 make it a rational target
for therapeutic intervention. Despite considerable evidence
implicating CEACAM6 as an important determinant of the
malignant phenotype, its role in cellular invasiveness has not
been examined.
Here, we characterise for the first time the role of CEACAM6,
and its downstream signalling targets, in determining pancreatic
adenocarcinoma cellular invasiveness. Our results indicate that
levels of CEACAM6 expression modulate pancreatic adenocarci-
noma cellular invasiveness.
MATERIALS AND METHODS
Cells and cell culture
Capan2 and BxPC3 cells were obtained from the American Type
Culture Collection (ATCC, Rockville, MD, USA). The Capan2 cell
line is derived from a well-differentiated human pancreatic ductal
adenocarcinoma. BxPC3 is derived from a moderately differen-
tiated human pancreatic ductal adenocarcinoma (Berrozpe et al,
1994; Sipos et al, 2003). Cells were maintained in Dulbecco’s
modified Eagle medium (DMEM) containing 10% foetal bovine
Received 9 March 2004; revised 14 June 2004; accepted 6 July 2004;
published online 17 August 2004
*Correspondence: Dr EE Whang; E-mail: ewhang1@partners.org
British Journal of Cancer (2004) 91, 1384–1390
& 2004 Cancer Research UK All rights reserved 0007– 0920/04 $30.00
www.bjcancer.com
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
sserum (FBS, Gibco BRL, Gaithersburg, MD, USA), and were
incubated in a humidified (371C, 5% CO2) incubator, grown in
75cm
2 culture flasks and passaged upon reaching 80% confluence.
Expression vector construction and transfection
Poly-A RNA was reverse transcribed using an anchored oligo-dT
primer with an XhoI restriction site. Double-stranded CEACAM6
cDNA was prepared and ligated into EcoRI adaptors, digested with
XhoI, ligated into the pOTB7 vector and transferred to the pIRES
expression plasmid (termed pIRES-CEACAM6). Cells were trans-
fected with pIRES-CEACAM6 or pIRES-eGFP, which acted as a
control, using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA)
in accordance with the manufacturer’s protocol. Stable clones were
selected by continuous treatment with G418 (Gibco, 0.8mgml
 1).
Constitutively active (myristoylated) Akt (myr-Akt), constitutively
active Src (SrcY529F) and dominant-negative Src (Src(K296R/
Y528F)) expression constructs were obtained from Upstate
(Waltham, MA, USA). Transient transfection was performed using
Lipofectamine 2000.
Retrovirally mediated CEACAM6 RNA interference (RNAi)
CEACAM6-specific and single base mismatch small-interfering
RNA (siRNA) expression constructs were generated by ligation of
inserts (containing XhoI and XbaI overhang sites) targeting the
following sequences into the pSuppressorNeo expression vector in
accordance with the manufacturer’s instructions (Imgenex, San
Diego, CA, USA): CEACAM6 (psiCEACAM6): 50-CCGGACAGTTC-
CATGTATA-30; Control (psiControl): 50-CCCGACAGTTCCATG-
TATA-30. Correct insert ligation was confirmed by absence of
linearisation by SalI. Vectors were expanded in competent
Escherichia coli. 293 packaging cells (ATCC) were transfected with
retroviral vectors, using Lipofectamine 2000 (Invitrogen, Carlsbad,
CA, USA), and selected for stable retrovirus production using
G418. Pancreatic adenocarcinoma cells were exposed to retrovirus-
containing supernatant for 16h in the presence of polybrene
(Sigma, St Louis, MO, USA). Stable selection of transfected clones
was achieved using G418. Clones were maintained in 500mM G418.
Western blotting
Cells were harvested and rinsed twice with PBS. Cell extracts
were prepared with lysis buffer (20mM Tris, pH 7.5, 0.1% Triton X,
0.5% deoxycholate, 1mM PMSF, 10mgml
 1 aprotinin, 10mgml
 1
leupeptin) and cleared by centrifugation at 12000g,4 1C. Total
protein concentration was measured using the BCA assay kit
(Sigma, St Louis, MO, USA) with bovine serum albumin as a
standard, according to the manufacturer’s instructions. Cell
extracts containing 30mg total protein were subjected to 10%
SDS/PAGE, and the resolved proteins transferred electrophoreti-
cally to PVDF membranes (Invitrogen, Carlsbad, CA, USA). Equal
protein loading was confirmed by Coomassie (BioRad, Hercules,
CA, USA) staining of the gel. After blocking with PBS containing
0.2% casein for 1h at room temperature, membranes were
incubated with 3–5mgml
 1 antibody in PBS containing 0.1%
Tween 20 overnight at 41C. Anti-CEACAM6 and anti-CEA
monoclonal antibodies were obtained from InnoGenex
(San Ramon, CA, USA), anti-c-Src monoclonal antibody
was obtained from Upstate Biotechnology (Lake Placid, NY,
USA). Chemoluminescent detection (Upstate, Lake Placid, NY,
USA) was performed in accordance with the manufacturer’s
instructions. The CEACAM6 signal was quantified using ImagePro
Plus software version 4.0 and normalised to that of actin. Blots
were performed in triplicate. Mean densitometric values (7s.d.)
are shown.
c-Src tyrosine kinase assay
c-Src tyrosine kinase activity was determined using a commercially
available kinase assay kit (Sigma, St Louis, MO, USA), according to
the manufacturer’s instructions. c-Src immunoprecipitates (20mg
total protein) were prepared using anti-c-Src monoclonal antibody
immobilised onto protein G sepharose beads (Zymed Laboratories
Inc., San Francisco, CA, USA). Immunoprecipitates were washed
and dissolved in tyrosine kinase buffer (final solution containing
0.3mM ATP) and incubated for 30min in 96-well plates coated
with tyrosine kinase substrate solution (poly-Glu-Tyr). Phos-
phorylated substrate was quantified by chromogenic detection
using horseradish peroxidase-conjugated anti-phosphotyrosine
antibody. Optical densities were determined at 492nm using a
Vmax microplate spectrophotometer. c-Src kinase activity was
compared to an epidermal growth factor receptor standard. Kinase
assays were performed in triplicate with four determinations per
condition.
Invasion assay
Cellular invasion was quantified using a modified Matrigel Boyden
chamber assay. The BD BioCoat Matrigel invasion chamber (BD
Bioscience, Bedford, MA, USA) was used according to the
manufacturer’s instructions. In all, 2.5 10
4 pancreatic cancer
cells in serum-free media were seeded onto Matrigel-coated filters.
In the lower chambers, 5% FBS was added as a chemoattractant.
After 24h incubation, the filters were stained with Diff-Quikt kit
(BD Biosciences), and the number of cells that had invaded
through the filter was counted under magnification (randomly
selected high-power fields). The counting was performed for three
fields in each sample, and mean values from three independent
experiments were calculated. The role of MMP-9 was determined
by performing invasion assays in the presence of 10mgml
 1 anti-
MMP-9 neutralising antibody or control (irrelevant) immunoglo-
bulin (IgG).
MMP-9 activity assay
MMP-9 activities of cell lysates were assessed using the
colorimetric Biotrak MMP-9 activity assay (Amersham, Piscat-
away, NJ, USA), in accordance with the manufacturer’s instruc-
tions. Optical densities were quantified using a Vmax microplate
spectrophotometer at a wavelength of 405nm, referenced to
650nm. Three samples were used for each experimental condition.
Experiments were performed in triplicate and mean values
calculated.
Nude mouse xenograft model
Male athymic nu/nu mice, 5 weeks of age, weighing 20–22g and
specific pathogen-free, were obtained from Charles River Labora-
tories (Wilmington, MA, USA). Mice were housed in microisolator
cages with autoclaved bedding in a specific pathogen-free facility
with 12h light–dark cycles and were maintained in accordance
with the guidelines of the Harvard Medical Area Standing
Committee on Animals and with the United Kingdom Co-
ordinating Committee on Cancer Research (UKCCCR) Guidelines
for the Welfare of Animals in Experimental Neoplasia (Workman
et al, 1998). Mice were anaesthetised with intraperitoneal ketamine
(200mgkg
 1), xylazine (10mgkg
 1) and xenografted with 10
6
pancreatic adenocarcinoma cells in 75ml PBS by subcutaneous
implantation. In all, 10 mice received psiCEACAM6 transfectants
and 10 mice received psiControl transfectants. After 6 weeks,
necropsy was performed and tumours were excised. Levels of
CEACAM6 expression and MMP-9 activities of tumour lysates
were determined by Western blotting (relative to actin) and
Biotrak assay (controlling for total protein), respectively.
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sStatistical analysis
Differences between groups were analysed using Student’s t-test,
multifactorial ANOVA of initial measurements and Mann–
Whitney U-test, for nonparametric data, as appropriate, using
Statistica 5.5. software (StatSoft, Inc, Tulsa, OK, USA). In cases in
which averages were normalised to controls, the standard
deviations of each nominator and denominator were taken into
account in calculating the final standard deviation. Po0.05 was
considered statistically significant.
RESULTS
Overexpression of CEACAM6 increases Capan2 pancreatic
adenocarcinoma cellular invasiveness
CEACAM6 overexpression was induced in Capan2 cells,
which inherently express a very low level of this molecule
(Gardner-Thorpe et al, 2002; Duxbury et al, 2004b). Two
stable CEACAM6-overexpressing clones (pIRES-CEACAM6.1 and
pIRES-CEACAM6.2) were established and overexpression
of CEACAM6 was confirmed by Western blot analysis
(Figure 1A). CEACAM6 expression in pIRES-CEACAM6.1 and
pIRES-CEACAM6.2 transfectants was 16- and 30-fold that
of control cells, respectively. Empty vector (pIRES) transfectants
exhibited no change in CEACAM6 expression, relative to
parental Capan2 cells. Cellular invasiveness towards a 5%
FBS chemoattractant was quantified using a modified
Matrigel Boyden chamber assay. pIRES transfectants and
mock-transfected cells (Capan2) served as controls and did
not differ in their cellular invasiveness. The cellular invasiveness
of pIRES-CEACAM6.1 was 5.7-fold that of control,
pIRES-CEACAM6.2 invasiveness was six-fold that of control
(Figure 1B).
Retrovirally mediated RNAi specific for CEACAM6
suppresses CEACAM6 expression
BxPC3 cells were used to assess the potential utility of retrovirally
mediated RNAi as an approach to silence CEACAM6 expression
in pancreatic adenocarcinoma cells. This cell line was selected
as it inherently expresses high levels of CEACAM6 (Gardner-
Thorpe et al, 2002; Duxbury et al, 2004b). RNA interference
induced by a siRNA-generating retroviral vector was used
to suppress CEACAM6 expression. Total levels of CEACAM6
expression, determined by Western blot, were reduced by
over 80% in BxPC3 cells stably transfected with the CEACAM6-
specific siRNA-generating retroviral vector (psiCEACAM6).
CEACAM6 expression was unaffected by the control
retrovirus (psiNeo), relative to uninfected cells (Figure 2).
The specificity of the retrovirus was demonstrated by
Western blotting for the closely related CEACAM family member,
CEA. Levels of CEA expression were unaffected by either
retrovirus.
Retrovirally mediated RNAi specific for CEACAM6
attenuates BxPC3 pancreatic adenocarcinoma cellular
invasiveness
To assess the functional consequences of suppressing CEACAM6
expression, we quantified the ability of psiCEACAM6 transfectants
to invade through a Matrigel simulated basement membrane in a
modified Boyden chamber, relative to psiNeo transfectants and
untreated BxPC3 cells. The cellular invasiveness of psiCEACAM6
transfectants through Matrigel towards a 5% FBS chemoattractant
was 3.2-fold less than that of both psiNeo transfectants and
untreated BxPC3 cells (Figure 3A). Cellular invasiveness of psiNeo
transfectants did not significantly differ from that of untreated
BxPC3 cells. Although we have previously shown that modulation
of CEACAM6 expression does not affect cellular proliferation of
pancreatic adenocarcinoma cells (Duxbury et al, 2004b), it was
important to determine the effect of retroviral infection on BxPC3
cellular proliferation. Proliferation of untreated cells, as well as
cells exposed to CEACAM6-specific or control retrovirus, was
quantified by MTT assay. We observed no significant difference in
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Figure 1 (A) Stable overexpression of CEACAM6 was confirmed in
two Capan2-derived transfectants, pIRES-CEACAM6.1 and pIRES-CEA-
CAM6.2, by Western blotting. Representative example with mean
densitometric values (7s.d.) from triplicate blots. *Po0.05 vs pIRES
(empty vector) transfectants. (B) Cellular invasiveness in the Matrigel
Boyden chamber assay was significantly increased in both pIRES-
CEACAM6.1 and pIRES-CEACAM6.2 transfectants. Values are means
(7s.d.) from triplicate experiments. *Po0.05 vs pIRES transfectants.
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Figure 2 Stable suppression of CEACAM6 expression was demon-
strated in BxPC3 psiCEACAM6 transfectants, by Western blot analysis.
CEA expression did not significantly differ among the transfectants.
Representative example with mean densitometric values (7s.d.) from
triplicate blots. *Po0.05 vs both psiNeo (empty vector) and psiControl
transfectants.
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transfectants, indicating not only that CEACAM6 expression is
not essential for cellular survival and proliferation, but also that
retroviral infection does not induce significant cytotoxicity
(Figure 3B).
Roles for c-Src and MMP-9 in CEACAM6-dependent
cellular invasiveness
Src kinases are known to associate with GPI-anchored proteins,
including those of the CEACAM family, and appear to play
an important role in transducing downstream signalling
events (Stefanova et al, 1991; Brown, 1993; Skubitz et al, 1995).
We have previously shown that the Src family kinase inhibitor
pyrazolopyrimidine (PP2) inhibits pancreatic adenocarcinoma
cellular invasiveness in association with dephosphorylation
of the prototype Src family kinase, c-Src, and suppression
of MMP-2 and MMP-9 activities (Ito et al, 2003). Further evidence
supports an important role for c-Src in modulating expression
of MMP-9, in particular, in human cancer cells (Sato and
Seiki, 1993; Recchia et al, 2003). We speculated that c-Src
may play a role in the CEACAM6-dependent component of the
invasive cellular phenotype and that this may occur through
modulation of MMP-9 expression. In order to test this hypothesis,
we first examined c-Src kinase activity following overexpression of
CEACAM6, using a c-Src-specific in vitro kinase assay. Next, we
examined the effect of retroviral CEACAM6-specific RNAi on c-Src
activity. Both pIRES-CEACAM6.1 and pIRES-CEACAM6.2 trans-
fectants exhibited increased cellular c-Src activities, relative to
control transfectants. Conversely, suppression of CEACAM6
expression was associated with a significant decrease in c-Src
activity (Figure 4).
Cellular MMP-9 activity was assessed by Biotrak assay. Both
pIRES-CEACAM6.1 and pIRES-CEACAM6.2 transfectants exhibit
significantly higher MMP-9 activities than both parental Capan2
cells and empty vector transfectants (Figure 5A). Furthermore,
addition of neutralising MMP-9 antibody, but not control isotype-
matched irrelevant IgG, attenuated the cellular invasiveness of
CEACAM6.1 and pIRES-CEACAM6.2 transfectants by 81 and 77%,
respectively (Figure 5B). Inhibition of c-Src activity using a
dominant-negative c-Src construct suppressed pIRES-CEACAM6.1
and pIRES-CEACAM6.2 cellular invasiveness by 48 and 65%,
respectively (Figure 5C), and almost completely abolished the
elevated MMP-9 activities exhibited by these transfectants
(Figure 5D).
In order to examine the role of c-Src in mediating the effects of
CEACAM6 on the invasive phenotype further, we tested the effects
of expression of constitutively active c-Src on psiCEACAM6
transfectants. In keeping with our previous findings, introduction
of constitutively active c-Src was sufficient to induce significant
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Figure 3 (A) Cellular invasiveness of psiCEACAM6 transfectants in the
Matrigel Boyden chamber assay was significantly reduced, relative to
psiNeo and psiControl transfectants. Values are means (7s.d.) from
triplicate experiments. *Po0.05 vs both psiNeo and psiControl transfec-
tants. (B) Cellular proliferation of psiCEACAM6 transfectants, quantified by
MTT assay, did not significantly differ from that of psiNeo or psiControl
transfectants. Values are means (7s.d.) from triplicate experiments.
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Figure 4 Both pIRES-CEACAM6.1 and pIRES-CEACAM6.2 Capan2-derived transfectants exhibited increased c-Src kinase activity, relative to pIRES
transfectants. Conversely, suppression of CEACAM6 expression was associated with decreased c-Src kinase activity in BxPC3-derived psiCEACAM6
transfectants. Values are means (7s.d.) from triplicate experiments. *Po0.05 vs pIRES transfectants.
wPo0.05 vs psiControl and psiNeo transfectants.
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Figure 5 (A) MMP-9 activities were significantly increased in pIRES-CEACAM6.1 and pIRES-CEACAM6.2 transfectants, relative to pIRES transfectants.
psiCEACAM6 transfectants exhibited significantly lower MMP-9 activity than both psiNeo and psiControl transfectants. Mean (7s.d.) from triplicate
experiments. *Po0.05 vs respective control transfectants. (B) Cellular invasiveness of pIRES-CEACAM6.1 and pIRES-CEACAM6.2 transfectants was
significantly attenuated by exposure to anti-MMP-9 monoclonal antibody, but not isotype-matched irrelevant IgG. Mean (7s.d.) from triplicate experiments.
*Po0.05 vs control IgG. Overexpression of dominant-negative Src (DN Src) significantly decreased cellular invasiveness (C) and MMP-9 activities (D)o f
pIRES-CEACAM6.1 and pIRES-CEACAM6.2 transfectants. Constitutively active c-Src induced a significant recovery of MMP-9 activity (C) and cellular
invasiveness (D) in psiCEACAM6 transfectants. Values are means (7s.d.) from triplicate experiments. *Po0.05 vs pUSE empty vector.
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psiCEACAM6 transfectants (Figure 5C and D). These observations
are consistent with a model in which CEACAM6 overexpression
increases cellular invasiveness, at least in part via a c-Src-
dependent increase in MMP-9 activity.
Effect of retrovirally mediated CEACAM6 knockdown on in
vivo MMP-9 activity
Mice were subcutaneously xenografted with either BxPC3 psiCEA-
CAM6 or psiControl transfectants. After 6 weeks, necropsy was
performed and tumour lysates prepared. Western blot analysis
confirmed lower levels of CEACAM6 expression in lysates from
psiCEACAM6-derived tumours, relative to those derived from
psiControl transfectants (Figure 6A). The mean MMP-9 activities
of lysates extracted from psiCEACAM6-derived tumours were
significantly lower than those of psiControl-derived tumours
(Figure 6B).
DISCUSSION
Pancreatic adenocarcinoma is among the most invasive of all
malignancies and locoregional tumour invasion is a common
cause of inoperability. The purpose of this study was to define the
role of CEACAM6 in determining the invasive cellular phenotype.
We have shown that overexpression of CEACAM6 enhances
cellular invasiveness and that post-transcriptional suppression of
CEACAM6 expression decreases the invasiveness of pancreatic
adenocarcinoma cells. CEACAM6 appears to exert its pro-invasive
effect in a c-Src-dependent manner, at least in part through
upregulation of MMP-9 activity.
Increasing evidence implicates CEACAM6 as a determinant of
malignant cellular behaviour and clinical outcome in a range
of human cancers (Hasegawa et al, 1993; Kodera et al, 1993;
Scholzel et al, 2000; Jantscheff et al, 2003). While CEACAM6
is recognised to act as an intercellular adhesion molecule
(Kuroki et al, 2001), it appears to have additional functions
in the context of malignancy (Ilantzis et al, 2002; Duxbury et al,
2004b). Despite lacking transmembrane and intracellular domains,
this GPI-anchored protein is able to influence intracellular
pathways central to cancer development and progression.
We have recently reported that overexpression of CEACAM6
is associated with an increased ability of pancreatic cancer cells
to survive under anchorage-independent conditions and that post-
transcriptional silencing of CEACAM6 expression suppresses
this ability, as well as impairing tumour progression in a
murine pancreatic adenocarcinoma xenograft model (Duxbury
et al, 2004b).
Glycosylphosphatidylinositol-anchored proteins have been
recognised to modulate activity of intracellular tyrosine kinases
(Stefanova et al, 1991; Brown, 1993; Skubitz et al, 1995) and
our results indicate that c-Src, which plays a central role in
pancreatic adenocarcinoma cellular invasion (Ito et al, 2003),
may act as an effector of CEACAM6 signalling. The 92kDa type IV
collagenase, MMP-9, plays a critical role in physiological
and pathological tissue remodelling. MMP-9 is transcriptionally
regulated in a c-Src-dependent manner through a GT box located
downstream of the AP-1 transcription factor-binding site of
its promoter (Sato et al, 1993). Modulation of c-Src tyrosine
kinase activity alters MMP-9 activity in a variety of tumour cell
types, including pancreatic adenocarcinoma cells (Ito et al, 2003;
Recchia et al, 2003). Our results are consistent with a model in
which CEACAM6 overexpression leads to a c-Src-dependent
increase in MMP-9 activity, resulting in increased cellular
invasiveness. We have recently examined the mechanisms through
which CEACAM6 modulates activity of c-Src kinase activity
(Duxbury et al, 2004a). CEACAM6 appears to be coupled to the
inhibitor of c-Src, Csk, in a caveolin-1 dependent manner.
Antibody-mediated crosslinking of CEACAM6 results in a
caveolin-1-dependent increase in c-Src activity in BxPC3 cells.
The increased c-Src activity exhibited by pIRES-CEACAM6.1 and
pIRES-CEACAM6.2 transfectants may reflect auto-aggregation of
the GPI-linked protein within membrane lipid rafts, as occurs
when other PGI-linked proteins are present at high density in the
cell membrane. We speculate that other membrane-associated
molecules may modulate CEACAM6 aggregation and signal
transduction, although this aspect of CEACAM6 biology requires
further study.
RNA interference offers an unrivalled opportunity to
silence expression of individual genes with a high degree of
specificity, allowing the roles of individual genes to be dissected
(Shi, 2003). However, one of the limitations of RNAi is
the requirement for transfection of cells with siRNA. Transfection
efficiency varies widely among cell types and exogenous siRNA
oligonucleotide-mediated RNAi is transient in nature, due to
siRNA dilution and degradation. Retroviral vectors have become
a popular means of transfecting cells with a high degree of
efficiency. This technique relies on the generation of short hairpin
RNA (shRNA), which is cleaved by intracellular nucleases to
yield active siRNA. This technique allows induction of stable
RNAi (Brummelkamp et al, 2002). Using this technique to silence
CEACAM6 expression, we have shown that levels of CEACAM6
expression can markedly influence the invasive cellular phenotype.
Retroviruses selectively infect dividing cells, making them a
rational vehicle for directed–directed gene silencing (Logg and
Kasahara, 2004). However, viral gene therapies have raised cause
for concern following well-publicised incidences of toxicity and
death (Raper et al, 2003). Although clinical evaluation of these
techniques will need to continue with caution, in vivo studies to
date have reported no signs of systemic toxicity (Brummelkamp
et al, 2002).
In summary, levels of CEACAM6 expression can modulate the
invasive phenotype in a c-Src-dependent manner, through
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Figure 6 (A) Sustained knockdown of CEACAM6 expression was
confirmed in the excised tumours by Western blot analysis. A
representative blot is shown. (B) MMP-9 activities in lysates obtained
from psiCEACAM6 transfectants were significantly lower than those of
psiControl-derived tumours. Mean values (7s.d.). *Po0.05 vs psiControl
transfectant tumours.
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salterations in cellular MMP-9 activity. These findings support the
premise that targeting CEACAM6 may represent a rational strategy
to attenuate the invasiveness of this malignancy. Novel
strategies targeting CEACAM6 and its downstream pathways
warrant further evaluation in the context of gastrointestinal
malignancy.
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